30Jun
Healthcare M&A prospers, despite fall in deal activity
The megadeals of 2019 may be off the table for now, but deal activity across healthcare and pharmaceuticals has proven resilient through the COVID-19 crisis - Although pharma, medical and biotech (PMB) M&A deal value for Q1 2020 came in at US$39.3 billion, 78% below the year before, this was primarily due to the outsized US$87.8 billion deal between Bristol-Myers Squibb and Celgene in early 2019....
By:
White & Case LLP
Related
On October 2, 2020, the Small Business Administration published new guidance outlining the procedure...
Read More >
Seyfarth Synopsis: Reversing course and overruling previous precedent, the Court of Appeals for the ...
Read More >
On Nov. 27, 2019, the New York Appellate Division for the Second Department affirmed New York’s lon...
Read More >
Key Points- Direct evidence of a plan to engage in repeated strikes to achieve a common goal establ...
Read More >
It’s no secret that California is typically viewed as the most employee-friendly state in the count...
Read More >
This national survey is a quick reference resource to the relevant laws and regulations governing ho...
Read More >